Generic Name and Formulations:
Nicotine 7mg/24hr, 14mg/24hr, 21mg/24hr; transdermal patch.
Dr. Reddy's Laboratories, Inc.
Indications for HABITROL:
Adjunct in smoking cessation therapy.
≥18yrs: Apply to clean, dry, nonhairy site on trunk or upper outer arm; rotate application site. Remove patch after 24 hours; if vivid dreams or other sleep disturbances occur, remove at bedtime and reapply in AM. >10cigarettes/day: initially one 21mg patch daily for 4 weeks; then one 14mg patch daily for 2 weeks, then one 7mg patch daily for 2 weeks, then stop. ≤10cigarettes/day: initially one 14mg patch daily for 6 weeks then one 7mg patch daily for 2 weeks, then stop. Max 1 patch/24hrs. Do not cut patch.
<18yrs: not recommended.
Concurrent smoking or use of other nicotine products.
Discontinue if irregular heartbeat, palpitations, allergic reaction, or symptoms of nicotine overdose occur. Heart disease. Post-MI. Arrhythmias. Hypertension. Depression. Asthma. Allergy to adhesive tape, other skin problems. Stomach ulcers. Diabetes. History of seizures. Low doses may be toxic to children and pets; discard properly. Pregnancy: not recommended. Nursing mothers.
Remove patch prior to MRI procedures. Smoking cessation potentiates theophylline, insulin, β-blockers, pentazocine, oxazepam, tricyclic antidepressants (eg, imipramine), caffeine, acetaminophen, adrenergic antagonists (eg, prazosin, labetalol), others. Smoking cessation antagonizes adrenergic agonists (eg, isoproterenol, phenylephrine), others.
Local irritation, GI upset, headache, dizziness, palpitations, hypertension.
Patch 7mg, 14mg—7, 14; 21mg—7, 14, 28
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML